Literature DB >> 22521903

Malignant migrating partial seizures of infancy controlled by stiripentol and clonazepam.

Dana Merdariu1, Catherine Delanoë, Nora Mahfoufi, Vanina Bellavoine, Stéphane Auvin.   

Abstract

The syndrome of malignant migrating partial seizures of infancy (MMPSI) is characterized by early onset of multiple seizure types and overall poor prognosis. Seizures are markedly drug resistant and few reports have suggested the efficacy of some antiepileptic drugs. We report one case of MMPSI in which prolonged seizure control is obtained with an association of clonazepam, levetiracetam and stiripentol, confirming thus the possibility of complete sustained seizure control in this epileptic syndrome. Of more than 60 cases reported to date, ours is the forth in which sustained complete control of seizures was obtained.
Copyright © 2012 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521903     DOI: 10.1016/j.braindev.2012.03.016

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  3 in total

Review 1.  Childhood Electroclinical Syndromes: a diagnostic and therapeutic algorithm.

Authors:  Pratibha Singhi
Journal:  Indian J Pediatr       Date:  2014-08-07       Impact factor: 1.967

Review 2.  Stiripentol in the Management of Epilepsy.

Authors:  Katherine C Nickels; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

3.  Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum.

Authors:  Amy McTague; Richard Appleton; Shivaram Avula; J Helen Cross; Mary D King; Thomas S Jacques; Sanjay Bhate; Anthony Cronin; Andrew Curran; Archana Desurkar; Michael A Farrell; Elaine Hughes; Rosalind Jefferson; Karine Lascelles; John Livingston; Esther Meyer; Ailsa McLellan; Annapurna Poduri; Ingrid E Scheffer; Stefan Spinty; Manju A Kurian; Rachel Kneen
Journal:  Brain       Date:  2013-04-18       Impact factor: 13.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.